Stock info Jazz Pharmaceuticals | Filter  Basic-Info

Jazz Pharmaceuticals

Jazz Pharmaceuticals mainly operates in the pharmaceutical sector. The period from 2006 till the end of 2016 the international sector gained around 75 percent. Over the past 5 years the sector is 147 percent higher.

The past year was a profitable year for Jazz Pharmaceuticals investors

Over the last 12 months, that were loss-making period for the investors in Jazz Pharmaceuticals, the stock lost around 24 percent. Over the past 5 years Jazz Pharmaceuticals' stock rose at around 191 percent in value. Jazz Pharmaceuticals's revenues between 2011 and 2015 were very fluctuating and moved between 585,98 million dollars and 1,32 billion dollars. The net results between 2011 and 2015 were far from constant and fluctuated between 124,98 million dollars and 329,53 million dollars.

The American company didn't pay out any dividends (in the past 5 years).

Jazz Pharmaceuticals' balance mostly financed with equity

At the end of 2015 the pharmaceutical company's balance sheet was worth 3,36 billion dollars. The total debt was around 1,76 billion dollars. This is 52,42 percent of the total balance sheet. At the end of 2016 the American company was traded with a price/earnings-ratio of around 28. So investors paid 28 times the company's 2015's EPS. Based on it's price/earnings-ratio and dividend yield the American stock can be seen as a growth stock.

At the end of 2015 the American company's market capitalization equaled around 8,41 billion dollars. At the end of 2015 the American company had around 61,31 million stocks listed.

All Jazz Pharmaceuticals's annual reports can be found here. More information about Jazz Pharmaceuticals can be found it's website. .